Pancreatic Precursor Cell Reprogramming via Small Molecule Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for amplifying and differentiating pancreatic cells are complex, costly, and carry ethical and carcinogenic risks, with low efficiency in producing insulin-secreting cells, and gene-editing methods pose risks of non-specific and off-target deletions.
Innovation Solution
A method involving pancreatic tissue from a mammalian duct, using discontinuous density gradient centrifugation and an amplifying medium with specific small molecule compounds to induce reprogramming of primary cells into pancreatic precursor-like cells, which are then differentiated into islet-like cells using a differentiation medium, avoiding the use of embryonic stem cells and gene-editing risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If embryonic stem cells are used to induce cells with insulin secretion function, then the proliferation capacity is improved, but the induction complexity and cost increase, and the proportion of functional cells remains low
Solution Approach 1:
The patent uses small molecule compounds to modulate signaling pathways (WNT, TGF-β, ROCK) and induces reprogramming of pancreatic ductal cells into precursor-like cells with enhanced proliferation capacity and insulin secretion function, avoiding the complexity of embryonic stem cell induction while achieving high functional cell proportion
2Reliability
If embryonic stem cells are used for cell replacement therapy, then the insulin secretion function is improved, but ethical restrictions and carcinogenic risks arise
Solution Approach 1:
The patent extracts and utilizes pancreatic ductal cells from mammalian pancreas as a safe alternative to embryonic stem cells. These cells are enriched through density gradient centrifugation and reprogrammed into precursor-like cells that can differentiate into functional insulin-secreting cells without ethical concerns or carcinogenic risks
3Reliability
If gene-editing methods are used to change gene sequence, then the cell function is improved, but non-specific and off-target deletion risks increase
Solution Approach 1:
The patent replaces gene-editing methods with a chemical reprogramming approach using small molecule compounds that modulate signaling pathways (WNT agonist, TGF-β inhibitor, ROCK inhibitor) to induce pancreatic ductal cells to differentiate into precursor-like cells, achieving enhanced cell function without genetic modification and associated off-target risks
4Manufacturing precision
If discontinuous density gradient centrifugation is used to purify pancreatic ductal cells, then the purity of primary cells is improved, but the processing time and complexity increase
Solution Approach 1:
The patent segments the pancreatic tissue into different cell populations using discontinuous density gradient centrifugation with multiple demixing agents of different densities, collecting cell clusters at each density gradient junction to enrich pancreatic ductal cells while removing islet cells and acinar cells, achieving high purity through systematic separation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively produces pancreatic precursor-like cells with high yield and islet function, reducing ethical and carcinogenic risks, and achieving stable insulin secretion, thereby providing a viable replacement for islet cells.
Implementation Method 1
Performing digestion, resuspension, and discontinuous density gradient centrifugation treatment to the pancreatic tissue in sequence, collecting the cell clusters at each density gradient junction
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
An amplifying method of pancreatic cells is provided. The amplifying method includes performing digestion, resuspension, discontinuous density gradient centrifugation treatment and amplifying treatment sequentially. The mammalian pancreatic duct is used as the source of pancreatic precursor-like cells in the amplifying method of the invention, and islet cells and acinar cells in the cell clusters obtained by the discontinuous density gradient centrifugation treatment are removed. It is beneficial to improve the yield of the pancreatic precursor-like cells availably, and avoid the ethical restrictions and possible carcinogenic risks caused by using the embryonic stem cells. The amplifying medium used comprises a reprogramming substance composed of several small molecule compounds. It can avoid the risks of non-specific and off-target deletion that are easily caused by the use of the gene-editing methods to change the gene sequence. The invention also provides a differentiation method and an application of the pancreatic precursor-like cells obtained by the amplifying method.